Q: since the number of hospital surgeries will grow post covid please list your 2 favourite companies that will benefit . please name a pairing of companies with little or no overlap that will benefit under this scenario. thanks Richard
Q: Happy New Year to all. With the new pill to help people with Covid 19 do you feel PFE will continue to rise or at least hold steady? The variants may be with us for awhile!
Thankyou for a solid year and here's to a HEALTHY 2022
Q: I am under the impression a company must release any material news asap? If so, is it a fair presumption a release like this means the news isnt material? "Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference"
Q: Looking through past questions, your comments and outlook on PRN are quite positive, yet I don't see much to like about this stock. The company has missed earnings estimates for the past 2 years (all substantial losses), and its revenue seems to be growing (somewhat) but it's been inconsistent, along with several other negative signs (e.g. 27x sales, inherently higher risk of a small company). Could you please explain your reasoning so I can better understand what I'm missing. Thanks.
Q: This company has been coming down for some time. What are your views regarding adding more shares to reduce the average cost. Would also appreciate your views re. short and medium term prospects for the company.
Also, I could not find symbol FRDM in your Dara base?
Thanks
Financial Performance has been mentioned as strongly profitable with a net profit margin over 45%. Year-over-year Quarterly revenue grew by almost 60%. Everything looked great. I took on a position and am now down over 10%. I know you never comment about personal rules one of which for myself is if it drops 10% below MV sell because only the pigs get slaughtered on wall street.
You're advice regarding what I should do (buy/hold/sell), is there any explanation you can provide why there there was a precipitous drop today, and would you remain bullish on this name?
Q: ABBV has had a good run recently. So good that it is now trading at a PE of approx. 32 from what I see. I see revenue has been consistently climbing, and P/CF appears to be a bit lower than it's historical numbers. However, according to Morningstar it I see that it is trading at approx. 1.2 above fair value - historically high for ABBV.
What are your thoughts on this stock? Will the revenue drop a year or two once the Humira patent cliff is hit? I'm assuming this may all be priced in. Just wondering if in your opinion the valuation has become stretched, or can be justified.
Q: Some comments on the merits of this company. A happy and Holy Christmas to all you staff and a sin ere thank you for your great and affordable service.
Q: JIM CRAMER OF CNBC RECOMMENDED ELI LILLY BECAUSE OF THEIR PIPELINE AND ETC. THEREFORE, I WAS THINKING OF SWITCHING JOHNSON AND JOHNSON FOR ELI LILLY, WHAT SAY YOU?
Q: Hi Peter and team,
While Becton Dickinson and Stryker seem to have a lot in common (medical supplies, joint replacement, etc.) their performance has deviated greatly in recent years; (over the past year, less than 1% gain for BDX but almost 12% for SYK). The one I own (naturally) is BDX, which also has a lower P/E and a higher dividend. Two questions: (i) any idea why BDX has underperformed SYK so much; (ii) would you sell, hold on, or buy more of what many analysts say is a well-run company in a demographically promising business?
Thanks!